Welcome!

Agile Computing Authors: Yeshim Deniz, Elizabeth White, Zakia Bouachraoui, Liz McMillan, Pat Romanski

News Feed Item

COPD Drug Market Opportunity and Clinical Pipeline Analysis

DALLAS, April 19, 2014 /PRNewswire/ --


ReportsnReports.com offers COPD Drug Market Opportunity & Clinical Pipeline Analysis 2014 to 2018 industry research report in its store at http://www.reportsnreports.com/reports/280894-copd-drug-market-opportunity-clinical-pipeline-analysis.html .

The global market for COPD has been estimated to be close to US$ 12 billion in 2013. With a high number of new and more efficient and convenient drugs crowding the market, it is expected that this market would grow at a CAGR of 8% to reach close to US$ 17.5 billion by 2018. Some of the drugs which are major contributors to this growth include once-daily LABA/LAMA fixed-dose combinations such as QVA-149, umeclidinium bromide/vilanterol and olodaterol/tiotropium. By 2018, it is expected that the combinations of LABA/LAMA would the leading drugs driving sales in the COPD therapy market and by 2021, these drugs would account for more than 25% of the market share. While in 2013, close to 50% of the global market was accounted by the US, with the other regions together accounting for 50%. However, it is expected that by 2018, the share of the USA would reduce marginally to 45%, while the lost share of this region would be taken over by the Asian region.

Companies discussed in COPD Drug Market Opportunity & Clinical Pipeline Analysis research report include Almirall, AstraZeneca, Boehringer Ingelheim, Bayer, Chiesi Farmaceutici, Forest Laboratories, Lallemand Pharma, Merck & Co, Novartis and Sunovion Pharmaceuticals. Order  a copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=280894 .

Close to 1 Billion people worldwide suffer from respiratory or pulmonary diseases. In the respiratory therapeutic domain, Asthma and COPD are the major categories, accounting for close to 75% of the total patient for respiratory or pulmonary diseases. Chronic obstructive pulmonary disease (COPD) is a disease which progresses in the lungs and requires treatment all through the life. It is an inflammatory disorder which is characterized by obstruction in the variable airflow and airway hyper-responsiveness to many intrinsic, genetic and environmental stimuli. These disorders have become one of the major reasons for disability and death. The prevalence and incidence of this disease is increasing worldwide.

Bronchodilators and polypharmacy dominates the treatment for this disease. It is expected that by 2020, COPD would account for more than 6 Million deaths across the globe annually. Inspite of significant investments in the development of novel agents to treat the disease, the COPD therapy area is generally dominated by inhaled bronchodilator therapies which only relieve symptoms, but do not completely cure the disease. There exist many opportunities for a disease-modifying therapy. However, the development of new COPD therapies is increasingly focusing on therapies which combine two bronchodilators into one inhaler.

ThisCOPD Drug Market Opportunity & Clinical Pipeline Analysis  Report Highlights:

• COPD Drug Market Overview
• COPD Patient Base: Global, US & Europe
• FDA & EMA Guidelines on Clinical Investigation of COPD Drugs
• COPD Drug Clinical Pipeline by Phase & Country
• COPD Drug in Development Phase: 174
• Majority of COPD Drugs in Preclinical Phase: 72
• Marketed COPD Drugs: 36
• Discontinued & Suspended COPD Drug Profiles

Other newly published reports on the pharmaceuticals industry available with us:

China Pharmaceutical Distribution Industry Report, 2013 market research says thanks to the continuous advancement in new medical reform, China's pharmaceutical distribution industry has maintained a fairly rapid growth in recent years, with the sales value showed a CAGR of roughly 20% in 2005-2013. Companies discussed in this report include China National Accord Medicines, Nanjing Pharmaceutical Co., Ltd (NPC), Chongqing Tongjunge, Shanghai No.1 Pharmacy, China National Medicines, Huadong Medicine, Cachet, Jointown, Realcan Pharmaceutical¸ Shanghai Pharma, Zhejiang Int'l Group, Zhejiang Zhenyuan and CNPIC. Complete report is available at http://www.reportsnreports.com/reports/280794-china-pharmaceutical-distribution-industry-report-2013.html .

Market Research Report on Global and Chinese Benzarone Industry, 2009-2019 is a professional and in-depth market survey on global and Chinese benzarone markets.  This report provides forecasts information on 2014-2019 Global and China Capacity, Production, and Production Value of Benzarone, 2014-2019 Benzarone Industry Cost and Profit Estimation, 2014-2019 Global and China Market Share of Benzarone, 2014-2019 Global and China Supply and Consumption of Benzarone and 2014-2019 China Import and Export of Benzarone. Complete report is available at http://www.reportsnreports.com/reports/280193-market-research-report-on-global-and-chinese-benzarone-industry-2009-2019.html .

List of Figures provided in COPD Drug Market Opportunity & Clinical Pipeline Analysis research report include:

Figure 1-1: Global - People Suffering With COPD (Million), 2013-2018

Figure 1-2: US - People Suffering With COPD (Million), 2013-2018

Figure 1-3: US - People Suffering With COPD by Age Group (%)

Figure 1-4: Europe - People Suffering With COPD (Million), 2013-2018

Figure 1-5: Europe - Death from COPD ('000) , 2005 & 2030

Figure 1-6: Global COPD Drug Market (US$ Billion), 2012-2018

Figure 1-7: Number of COPD Drugs in Clinical Trial by Phase, 2014

Figure 1-8: COPD Drugs in Clinical Trial by Phase (%), 2014

Figure 1-9: Number of Discontinued COPD Drugs in Clinical Trial by Phase, 2014

Figure 1-10: Discontinued COPD Drugs in Clinical Trial by Phase (%), 2014

Figure 1-11: Number of Suspended COPD Drugs in Clinical Trial by Phase, 2014

Figure 1-12: Suspended COPD Drugs in Clinical Trial by Phase (%), 2014

Figure 1-13: Number of No Development in COPD Drugs in Clinical Trial by Phase, 2014

Figure 1-14: No Development in COPD Drugs in Clinical Trial by Phase (%), 2014

About Us: 

ReportsnReports.com is an online market research reports library of 400,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Contact: 

Priyank Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel: +1-888-391-5441
[email protected]

http://www.deepresearchreports.com/cat/pharmaceuticals-market-research.html

Connect With Us on: 

Facebook: https://www.facebook.com/pages/ReportsnReports/191441427571689

LinkedIn: http://www.linkedin.com/company/reportsnreports

Twitter: https://twitter.com/marketsreports

Pinterest: http://www.pinterest.com/comeonseo/reportsnreports/


More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

IoT & Smart Cities Stories
Digital Transformation: Preparing Cloud & IoT Security for the Age of Artificial Intelligence. As automation and artificial intelligence (AI) power solution development and delivery, many businesses need to build backend cloud capabilities. Well-poised organizations, marketing smart devices with AI and BlockChain capabilities prepare to refine compliance and regulatory capabilities in 2018. Volumes of health, financial, technical and privacy data, along with tightening compliance requirements by...
"Avere Systems deals with data performance optimization in the cloud or on-premise. Even to this day many organizations struggle with what we call the problem of data gravity - 'Where should I put the data?' - because the data dictates ultimately where the jobs are going to run," explained Scott Jeschonek, Director Cloud Solutions at Avere Systems, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
If a machine can invent, does this mean the end of the patent system as we know it? The patent system, both in the US and Europe, allows companies to protect their inventions and helps foster innovation. However, Artificial Intelligence (AI) could be set to disrupt the patent system as we know it. This talk will examine how AI may change the patent landscape in the years to come. Furthermore, ways in which companies can best protect their AI related inventions will be examined from both a US and...
Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settlement products to hedge funds and investment banks. After, he co-founded a revenue cycle management company where he learned about Bitcoin and eventually Ethereal. Andrew's role at ConsenSys Enterprise is a mul...
DXWorldEXPO LLC, the producer of the world's most influential technology conferences and trade shows has announced the 22nd International CloudEXPO | DXWorldEXPO "Early Bird Registration" is now open. Register for Full Conference "Gold Pass" ▸ Here (Expo Hall ▸ Here)
CloudEXPO New York 2018, colocated with DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City and will bring together Cloud Computing, FinTech and Blockchain, Digital Transformation, Big Data, Internet of Things, DevOps, AI, Machine Learning and WebRTC to one location.
The best way to leverage your Cloud Expo presence as a sponsor and exhibitor is to plan your news announcements around our events. The press covering Cloud Expo and @ThingsExpo will have access to these releases and will amplify your news announcements. More than two dozen Cloud companies either set deals at our shows or have announced their mergers and acquisitions at Cloud Expo. Product announcements during our show provide your company with the most reach through our targeted audiences.
@DevOpsSummit at Cloud Expo, taking place November 12-13 in New York City, NY, is co-located with 22nd international CloudEXPO | first international DXWorldEXPO and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time t...
Contextual Analytics of various threat data provides a deeper understanding of a given threat and enables identification of unknown threat vectors. In his session at @ThingsExpo, David Dufour, Head of Security Architecture, IoT, Webroot, Inc., discussed how through the use of Big Data analytics and deep data correlation across different threat types, it is possible to gain a better understanding of where, how and to what level of danger a malicious actor poses to an organization, and to determin...
The hierarchical architecture that distributes "compute" within the network specially at the edge can enable new services by harnessing emerging technologies. But Edge-Compute comes at increased cost that needs to be managed and potentially augmented by creative architecture solutions as there will always a catching-up with the capacity demands. Processing power in smartphones has enhanced YoY and there is increasingly spare compute capacity that can be potentially pooled. Uber has successfully ...